Anakinra
Chemical formula: C₂₀H₂₃N₅O₇S₂ Molecular mass: 509.6 g/mol
Active ingredient description
Anakinra neutralises the biologic activity of interleukin-1α (IL-1α) and interleukin-1β (IL-1β) by competitively inhibiting their binding to interleukin-1 type I receptor (IL-1RI). Interleukin-1 (IL-1) is a pivotal pro-inflammatory cytokine mediating many cellular responses including those important in synovial inflammation.
Medicine classification
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC Group | Classification | |
|---|---|---|
| L04AC03 | Anakinra | L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors |
Product monographs
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Document | Type | Information Source | |
|---|---|---|---|
| KINERET Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) |
Medicines
Anakinra is an active ingredient of these brands:
Australia (AU)
Austria (AT)
Canada (CA)
Croatia (HR)
Cyprus (CY)
Estonia (EE)
Finland (FI)
France (FR)
Ireland (IE)
Israel (IL)
Italy (IT)
Lithuania (LT)
Netherlands (NL)
Poland (PL)
Romania (RO)
Spain (ES)
United Kingdom (UK)
United States (US)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.